185 related articles for article (PubMed ID: 26110425)
1. Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
Denard B; Pavia-Jimenez A; Chen W; Williams NS; Naina H; Collins R; Brugarolas J; Ye J
PLoS One; 2015; 10(6):e0129233. PubMed ID: 26110425
[TBL] [Abstract][Full Text] [Related]
2. CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
Denard B; Jiang S; Peng Y; Ye J
BMC Cancer; 2018 Aug; 18(1):813. PubMed ID: 30103710
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1.
Denard B; Lee C; Ye J
Elife; 2012 Dec; 1():e00090. PubMed ID: 23256041
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
[TBL] [Abstract][Full Text] [Related]
5. [Effects of SIPL1 screened by suppression subtractive hybridization (SSH) on biological function and drug resistance of renal cell carcinoma cells].
Li CY; Yao AM; Chang XN; Guo YH; Xu R
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):897-903. PubMed ID: 24506958
[TBL] [Abstract][Full Text] [Related]
6. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
[TBL] [Abstract][Full Text] [Related]
7. Cyclic AMP responsive element-binding protein promotes renal cell carcinoma proliferation probably via the expression of spindle and kinetochore-associated protein 2.
Zhuang H; Meng X; Li Y; Wang X; Huang S; Liu K; Hehir M; Fang R; Jiang L; Zhou JX; Wang P; Ren Y
Oncotarget; 2016 Mar; 7(13):16325-37. PubMed ID: 26824422
[TBL] [Abstract][Full Text] [Related]
8. OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.
Rose M; Schubert C; Dierichs L; Gaisa NT; Heer M; Heidenreich A; Knüchel R; Dahl E
Epigenetics; 2014 Dec; 9(12):1626-40. PubMed ID: 25625847
[TBL] [Abstract][Full Text] [Related]
9. Reduced CREB3L1 expression in triple negative and luminal a breast cancer cells contributes to enhanced cell migration, anchorage-independent growth and metastasis.
Mellor P; Kendall S; Smith S; Saxena A; Anderson DH
PLoS One; 2022; 17(7):e0271090. PubMed ID: 35802566
[TBL] [Abstract][Full Text] [Related]
10. Relationship between expression of drug-resistance factors and drug sensitivity in normal human renal proximal tubular epithelial cells in comparison with renal cell carcinoma.
Asakura T; Imai A; Ohkubo-Uraoka N; Kuroda M; Iidaka Y; Uchida K; Shibasaki T; Ohkawa K
Oncol Rep; 2005 Sep; 14(3):601-7. PubMed ID: 16077962
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
13. The membrane-bound transcription factor CREB3L1 is activated in response to virus infection to inhibit proliferation of virus-infected cells.
Denard B; Seemann J; Chen Q; Gay A; Huang H; Chen Y; Ye J
Cell Host Microbe; 2011 Jul; 10(1):65-74. PubMed ID: 21767813
[TBL] [Abstract][Full Text] [Related]
14. Sustained induction of collagen synthesis by TGF-β requires regulated intramembrane proteolysis of CREB3L1.
Chen Q; Lee CE; Denard B; Ye J
PLoS One; 2014; 9(10):e108528. PubMed ID: 25310401
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma.
Ferguson RE; Jackson SM; Stanley AJ; Joyce AD; Harnden P; Morrison EE; Patel PM; Phillips RM; Selby PJ; Banks RE
Int J Cancer; 2005 May; 115(1):155-63. PubMed ID: 15645438
[TBL] [Abstract][Full Text] [Related]
17. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
[TBL] [Abstract][Full Text] [Related]
18. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.
Liu J; Li M; Song B; Jia C; Zhang L; Bai X; Hu W
Urol Oncol; 2013 Feb; 31(2):264-70. PubMed ID: 21676631
[TBL] [Abstract][Full Text] [Related]
19. Flotillin-1 expression in human clear-cell renal cell carcinoma is associated with cancer progression and poor patient survival.
Zhang Y; Li J; Song Y; Chen F; Pei Y; Yao F
Mol Med Rep; 2014 Aug; 10(2):860-6. PubMed ID: 24913320
[TBL] [Abstract][Full Text] [Related]
20. AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.
Doñate F; Raitano A; Morrison K; An Z; Capo L; Aviña H; Karki S; Morrison K; Yang P; Ou J; Moriya R; Shostak Y; Malik F; Nadell R; Liu W; Satpayev D; Atkinson J; Joseph IB; Pereira DS; Challita-Eid PM; Stover DR
Clin Cancer Res; 2016 Apr; 22(8):1989-99. PubMed ID: 26589436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
